$KRRO News

Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

Korro Bio Announces Preclinical Results Showing KRRO-111 Potential To Treat Both Lung And Liver Manifestations Of Alpha-1 Antitrypsin Deficiency

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target

Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121

Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Korro to Participate in Upcoming Investor Conferences

HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target

Korro Bio Submits To Australian Alfred Health Human Ethics Committee To Start Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?

Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?

Korro Bio: RNA Editor Plots Way Back After AATD Study Fail - I'm Holding

One Korro Bio Insider Raised Stake By 19% In Previous Year

Korro to Present at the 2026 Jefferies Global Healthcare Conference